Lyme Disease

Condition: Lyme Disease  |  Category: Infectious and Inflammatory Health  |  Reviewed by: Brian Lamkin, DO

What Is Lyme Disease?

Lyme disease is a tick-borne infection caused by Borrelia burgdorferi in the United States and related Borrelia species worldwide, transmitted primarily by Ixodes scapularis (blacklegged ticks) in the Northeast and Midwest and Ixodes pacificus in the West. Acute Lyme typically presents with the characteristic expanding erythema migrans rash (present in 60 to 80 percent of cases) along with flu-like symptoms, often progressing to early disseminated disease affecting joints, nervous system, and heart within weeks to months. In a significant subset of patients, the disease progresses to a chronic persistent state involving coinfections, biofilm formation, and chronic inflammatory response.

The controversy in Lyme disease care does not exist because the disease is ambiguous. It exists because the testing is inadequate, the surveillance criteria were never intended as diagnostic criteria, and treatment guidelines from different professional societies (IDSA and ILADS) reach different conclusions about the appropriate duration and extent of antimicrobial therapy. Functional medicine does not resolve this debate, but it does approach each patient through a clinical assessment, expanded testing, coinfection evaluation, and integrated treatment that addresses persistent infection, biofilm, inflammation, immune dysregulation, and detoxification simultaneously rather than treating Borrelia in isolation.

Why Lyme Disease Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Chronic Lyme is rarely just Borrelia. The clinical picture involves multiple interacting mechanisms.

Persistent Borrelia Infection

Borrelia burgdorferi is a spirochete with remarkable ability to evade immune surveillance through antigenic variation, intracellular refuge, biofilm formation, and persister cell states. In vitro and animal evidence demonstrates that Borrelia can survive standard antibiotic treatment and remain viable for extended periods. Whether persistent infection drives symptoms in all chronic Lyme patients remains debated, but it is documented in some cases and justifies extended or combination antimicrobial therapy in appropriate patients.

Coinfections

Ixodes ticks frequently carry multiple pathogens. Coinfection rates vary by region but approach 50 percent or higher in some endemic areas. Babesia, a red blood cell parasite, produces air hunger, night sweats, and severe fatigue. Bartonella species produce characteristic linear rashes (stretch-mark appearance), neurological symptoms, and vascular manifestations. Ehrlichia and Anaplasma produce fever patterns with leukopenia and thrombocytopenia. Coinfection treatment frequently differs from Borrelia treatment and is essential for clinical response.

Biofilm and Persister Cells

Borrelia can form biofilms (aggregated bacteria protected by extracellular matrix) and enter dormant persister states that are highly resistant to conventional antibiotics targeting actively dividing bacteria. Biofilm disruption protocols (enzymatic, herbal, and pharmacological) and combination antibiotics targeting persister cells (such as disulfiram in research contexts) address this mechanism. Standard single-antibiotic protocols do not address biofilm or persister populations.

Inflammatory Response and CIRS Features

In genetically susceptible patients, Lyme infection can trigger a chronic inflammatory response syndrome that persists even after the infection is treated. This CIRS-like state is characterized by elevated C4a, elevated TGF-beta-1, suppressed MSH, and other biomarkers similar to mold illness. These patients require inflammatory modulation alongside antimicrobial therapy and may benefit from elements of the CIRS protocol.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The patient with classic EM rash and negative early serology: tick bite 3 weeks ago while hiking. Expanding bullseye rash. Flu-like symptoms. Conventional serology negative (too early for antibody development). Treatment initiated based on clinical presentation with doxycycline 200mg daily for 28 days. Rash and systemic symptoms resolved. Early treatment prevented disseminated disease.
• The patient with 5 years of "unexplained" chronic illness: fatigue, brain fog, joint pain, POTS, sleep disruption, anxiety over 5 years. Seen by 12 specialists. Conventional Lyme testing negative. Extended history reveals hiking in Lyme-endemic area 6 years ago with unremembered tick exposure. IGeneX Western blot positive with 5 bands. Babesia duncani IgG positive. Bartonella henselae IgG positive. Treatment initiated with tiered antimicrobial protocol plus biofilm disruption, inflammatory support, and detoxification. Significant improvement over 18 months.
• The chronic Lyme patient with CIRS features: previously treated for documented Lyme, persistent symptoms for 4 years despite multiple antibiotic courses. CIRS biomarkers reveal elevated C4a, elevated TGF-beta-1, low MSH. HLA-DR dreaded haplotype. This patient has chronic inflammatory response triggered by Lyme in a genetically susceptible host. Treatment requires both continued antimicrobial therapy for any persistent infection AND CIRS protocol for the inflammatory response syndrome.

Treatment and Optimization Strategy

Integrated Lyme and Coinfection Protocol

What Most Doctors Miss

• Standard Lyme testing is not designed for clinical diagnosis: the CDC two-tier criteria were developed for epidemiological surveillance. A negative test in a patient with compatible history and symptoms does not rule out Lyme. Clinical diagnosis and expanded testing are both needed.
• Coinfections are frequently the driving problem: patients who respond partially to Borrelia-directed therapy but continue to have symptoms often have untreated Babesia or Bartonella. Coinfection testing should be standard in chronic presentations.
• Chronic Lyme patients often have CIRS features: the inflammatory biomarker pattern in many chronic Lyme patients resembles mold illness. These patients need CIRS protocol elements alongside antimicrobial therapy, not antimicrobials alone.
• Treatment duration is individualized: the 10 to 21 day protocol is appropriate for early localized disease. Disseminated and chronic presentations frequently require extended or combination therapy. Rigid adherence to short-course treatment for all presentations produces treatment failure.

When to Seek Medical Care

If you have experienced tick exposure in a Lyme-endemic area with or without a recognized tick bite, if you have had an erythema migrans rash, or if you have experienced unexplained multisystem symptoms including fatigue, cognitive dysfunction, joint pain, and autonomic symptoms that have not responded to standard evaluation, comprehensive Lyme and coinfection testing along with evaluation for inflammatory response patterns is warranted. Do not accept a single negative conventional Lyme test as definitive rule-out in a compatible clinical picture.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Lyme Disease

At The Lamkin Clinic, Lyme disease evaluation includes expanded Western blot testing, T-cell assays, comprehensive coinfection panels (Babesia, Bartonella, Ehrlichia, Anaplasma), inflammatory biomarker assessment when CIRS features are suspected, and evaluation of HPA axis, thyroid, and mitochondrial function that are frequently disrupted in chronic presentations. Treatment integrates evidence-based antimicrobial protocols with coinfection-specific therapy, biofilm disruption, gut protection, Herxheimer management, inflammatory modulation, and systematic detoxification support. The goal is recovery, not perpetual treatment, through a coordinated approach to all the mechanisms driving persistent symptoms.

Related Conditions

Related Symptoms